EBV Reprograms B Cells in an Autoimmune-Like Fashion in Patients with COVID-19
Epstein-Barr virus (EBV) reprograms B cells in autoimmune disease. Reprogrammed EBV+ B cells activate nearby B and CD4+ T cells, via upregulated antigen presentation and costimulatory machinery, to drive autoimmune pathology. EBV reactivation is a known correlate of long COVID, which is a heterogeneous condition that can bear similarities to autoimmune disease. However, the mechanisms…
Epstein-Barr virus (EBV) has the ability to reprogram B cells in a manner similar to autoimmune diseases, according to a recent study. This reprogramming is thought to contribute to the development of autoimmune pathology. EBV reactivation is a known factor in long COVID, a condition that shares similarities with autoimmune diseases.
However, the exact mechanisms behind this association are still unclear. The study focused on EBV metabolically reprogrammed B cells in patients with COVID-19. They discovered that these EBV+ B cells emit stimulating signals to neighboring B and CD4+ T cells. COVID-19 patients who had higher levels of EBV+ B cells displayed disrupted lipid profiles, heightened autoantibody levels, and persistent post-acute symptoms that can be linked to this metabolic reprogramming and cell-cell interactions.
The researchers found that the EBV+ B cell signatures in patients with COVID-19 are comparable to those found in patients with lupus and multiple sclerosis. This similarity may indicate a shared pathway of EBV-driven dysfunction across these diseases.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.